Atrial stunning as predictor of early relapse into atrial fibrillation after cardioversion

International Journal of Cardiology

Volumn 110, Issue 3, 2006, Pages 427-428

  Climent, Vicente ^a   Marín, Francisco ^a   Monmeneu, Jose Vicente ^b   García de Burgos, Fernando ^b   Sogorb, Francisco ^a  

^a HOSPITAL GENERAL UNIVERSITARIO DE ALICANTE   (Spain)

^b HOSPITAL GENERAL UNIVERSITARIO DE ELCHE   (Spain)

Author keywords

Atrial fibrillation; Atrial stunning; Cardioversion; Echocardiography

Indexed keywords

ANGIOTENSIN II ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIGOXIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; ARTICLE; CARDIOVERSION; CONTROLLED STUDY; ECHOCARDIOGRAPHY; FOLLOW UP; HEART ATRIUM FIBRILLATION; HEART ATRIUM FUNCTION; HEART ATRIUM STUNNING; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RELAPSE; SINUS RHYTHM; STATISTICAL SIGNIFICANCE; STUNNED HEART MUSCLE; TREATMENT OUTCOME;

ATRIAL FIBRILLATION; ELECTRIC COUNTERSHOCK; HUMANS; MIDDLE AGED; PROGNOSIS; RECURRENCE; TIME FACTORS;

EID: 33744926901     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijcard.2005.11.041     Document Type: Article

References (9)

1. Thomas M.D., Kalra P.R., Jones A., Struthers A.D., and More R.S. Time course for recovery of atrial mechanical and endocrine function post DC cardioversion for persistent atrial fibrillation. Int J Cardiol 102 (2005) 487-491
2. Valencia J., Climent V.E., Marín F., et al. The efficacy of scheduled cardioversion in atrial fibrillation. Comparison of two schemes of treatment: electrical versus pharmacological cardioversion. Rev Esp Cardiol 55 (2002) 113-120
3. Harjai K.J., Mobarek S.K., Cheirif J., et al. Clinical variables affecting recovery of left atrial mechanical function after cardioversion from atrial fibrillation. J Am Coll Cardiol 30 (1997) 481-486
4. The Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Investigators. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 347 (2002) 1825-1833
5. Xu J., Cui G., Esmailian F., et al. Atrial extracellular matrix remodeling and the maintenance of atrial fibrillation. Circulation 109 (2004) 363-368
6. Marín F., Roldán V., Climent V., et al. Is thrombogenesis in atrial fibrillation related to matrix metalloproteinase-1 and its inhibitor, TIMP-1?. Stroke 34 (2003) 1181-1186
7. Boixel C., Fontaine V., Rücker-Martin C., et al. Fibrosis of the left atria during progression of heart failure is associated with increased matrix metalloproteinases in the rat. J Am Coll Cardiol 42 (2003) 336-344
8. Marín F, Pascual D, Roldán V, et al. Statins and postoperatory risk of atrial fibrillation following coronary artery by-pass grafting. Am J Cardiol in press.
9. Madrid A., Bueno M., Rebollo J., et al. Use of irbesartan to maintain sinus rhythm in patients with long-lasting persistent atrial fibrillation. Circulation 106 (2002) 331-336